Abstract
Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP1, KDM4-AC011523.2, TMEM135-CCDC67, LRRC59-FLJ60017 and Pten-NOLC1147 in the blood samples from 147 prostate cancer patients and 14 healthy individuals, using Taqman RT-PCR and Sanger’s sequencing. Similar analyses were also performed on 25 matched prostate cancer samples for matched-sample evaluation. Eighty-two percent blood samples from the prostate cancer patients were positive for MAN2A1-FER transcript, while 41.5% and 38.8% blood samples from the prostate cancer patients were positive for SLC45A2-AMACR and Pten-NOLC1, respectively. CCNH-c5orf30 and mTOR-TP53BP1 had low detection rates, positive in only 5.4% and 4% of the blood samples from the prostate cancer patients. Only 2 blood samples were positive for KDM4B-AC011523.2 transcript. Overall, 89.8% patients were positive for at least one fusion transcript in their blood samples. The statistical analysis showed varied sensitivity of fusion transcript detection in the blood based on the types of fusions. In contrast, the blood samples from all healthy individuals were negative for the fusion transcripts. Detection of fusion transcripts in the blood samples of the prostate cancer patients may be a fast and cost-effective way to detect prostate cancer.
Highlights
Prostate cancer remains one of the most lethal cancers for men in the United States
One study showed that up to 80% of prostate cancer samples were positive for Pten-NOLC1 gene fusion in the prostate cancer s amples[6], while the other study showed that a panel of eight fusion genes including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, TMEM135-CCDC67, CCNH-C5orf[30], LRRC59-FLJ60017, KDM4B-AC011523.2 and mTOR-TP53BP1 occurred in prostate cancer samples with various frequencies[7]
MAN2A1-FER, a fusion gene encoding for a tyrosine protein kinase, was present in 82.3% (121/147) blood samples from the prostate cancer patients, representing the most frequent fusion transcript detected in the blood of prostate cancer patients
Summary
Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. One study showed that up to 80% of prostate cancer samples were positive for Pten-NOLC1 gene fusion in the prostate cancer s amples[6], while the other study showed that a panel of eight fusion genes including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, TMEM135-CCDC67, CCNH-C5orf[30], LRRC59-FLJ60017, KDM4B-AC011523.2 and mTOR-TP53BP1 occurred in prostate cancer samples with various frequencies[7]. The presence of these fusion genes was associated with aggressive prostate cancers[7]. To investigate whether the fusion RNA is present in the blood samples of prostate cancer patients to detect prostate cancer, we analyzed nine fusion transcripts in the blood samples of 147 prostate cancer patients, and found that the fusion transcripts were frequently detectable in the blood samples of the prostate cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
